In preclinical studies, it was found that FSHR-targeted CAR T cells specifically kill FSHR+ ovarian cancer cells in vitro and in human ovarian cancer xenograft murine models and patient-derived FSHR+ xenograft models [112,113]. The gene discussed is FSHR; the disease is ovarian cancer.